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Tumour necrosis factor alpha (TNF-) is a multifunctional cytokine produced mainly by 
activated macrophages, T lymphocytes, and natural killer (NK) cells, and to a lesser extent by 
a variety of other cells, including fibroblasts, and tumour cells. TNF- is involved in disparate 
processes such as apoptosis, cell survival, inflammation, and immunity; its bioactivity is 
mainly regulated by two TNF- binding receptors (Bazzoni and Beutler 1996; Locksley et al. 
2001). TNF- is widely known to induce haemorrhagic necrosis in a certain set of tumour 
types. Earlier studies into the effect of TNF- on tumour cells in vitro mostly revealed slight 
antiproliferative and cytotoxic effects when TNF- was administered alone, and synergistic 
effects with other cytokines and chemotherapeutics (Sugarman et al. 1985; Rutka et al. 1988; 
Zouboulis et al. 1990; Sugarman et al. 1987; Kirstein et al. 1986; Lewis et al. 1987; Tomazic 
et al. 1988; Shibayama 1989; Chapekar et al. 1989; Manda et al. 1987; Mueller et al. 1996; 
Mutch et al. 1990; Helson et al. 1975; Zuber et al. 1988; Ha and Lau 1988; Rosenblum et al. 
1988; Schmiegel et al. 1988; Schiller et al. 1987; Nobuhara et al. 1987; Naomoto et al. 1987; 
Fransen et al. 1986). 
Radiotherapy represents one of the therapeutic options for patients with malignancies. The 
efficacy of this therapy is limited, amongst other things, by the fact that it cannot be delivered 
without hitting normal, healthy tissue surrounding the tumour, with radiation induced acute 
and chronic side effects. Radiation is known to induce DNA damage and the chromosomal 
instability of cells both from tumorous and normal tissue (Sakata et al. 2007). However, 
beyond this there are further mechanisms involved in the actions occurring after the exposure 
of cells and tissue to ionizing radiation, such as radiation induced apoptosis (Hasegawa et al. 
2002) and radiation induced changes in gene expression (Christiansen et al. 2006; 




Radiation therapy (RT) has not played a significant role in the management of hepatocellular 
carcinoma or liver metastases, because the liver has only limited tolerance to radiation, mated 
with the high risk of potentially fatal radiation induced liver disease (RILD). However, given 
the advances in modern radiotherapy techniques, for example taking into account the 
respiratory motion of the liver, the implementation of image guiding or stereotactic treatment, 
radiotherapy may now be applied to patients with a greater degree of safety (Krishnan et al. 
2008). 
Tumours are embedded in a rich cell microenvironment and radiotherapy not only targets 
cancer cells but also induces temporary and persistent changes in the local tissue 
microenvironment (Barcellos-Hoff and Cordes 2007). Thus, the effect of radiation on the 
tumour cells may be the result of a combined effect on tumour cells and on the cells of the 
microenvironment, contributing to both efficacy and toxicity (Hunter et al. 2006). One of the 
mechanisms here may be cell-cell interactions via pro-inflammatory cytokines, as radiation is 
known to induce an up-regulation of these agents in several cells, organs, and tissues 
(Herskind et al. 1998; Rübe et al. 2004). Thereby, cytokine mediated cell-cell interactions 
seem to play a decisive role in the development of acute and chronic normal tissue injuries 
following radiotherapy (Herskind et al. 1998; Rübe et al. 2004). Similarly, we recently 
demonstrated that cell-cell interactions via pro-inflammatory cytokines are involved in the 
early pathomechanisms following liver irradiation, leading to hepatocellular death and 
influencing radiation induced gene expression (Christiansen et al. 2007; Moriconi et al. 2008; 
Christiansen et al. 2004; Tello et al. 2008). Therefore, we hypothesize that cytokine mediated 
cell-cell interactions may be an important initial step towards RILD, which is a dose limiting 
complication in the radiotherapy of abdominal and especially hepatic malignancies (Lawrence 
et al. 1995; Dawson et al. 2002). Our data revealed that the pro-inflammatory cytokine TNF- 
is of particular interest in the processes taking place after liver irradiation, as radiation causes 




radiation induced apoptosis of liver macrophages, Kupffer cells, may lead to a release of 
TNF- in the microenvironment (Tello et al. 2008), followed by apoptosis of irradiated 
hepatocytes by radiation induced up-regulation of IB expression (Rave-Fränk et al. 2006). 
During the radiotherapy of hepatobiliary malignancies, TNF- may not only influence 
hepatocytes and liver macrophages but also hepatocellular or biliary tumour cells. However, 
the effect of TNF- and radiation, especially in combination, on the sensitivity of 
hepatocellular and biliary tumour cells has yet to be determined. Therefore, the aim of the 
present study was to evaluate the influence of TNF- and radiation alone or in combination 
on the viability of several hepatocellular and biliary tumour cells in vitro. Furthermore, 
radiation induced changes of TNF-, TNF receptors 1 and 2, as well as IB expression were 
evaluated to elucidate intracellular mechanisms and possible differences in the radiation 
induced changes in hepatocytes, in which the pro-apoptotic effect of TNF- after irradiation 





2. Material and Methods 
 
2.1    Reagents 
All chemicals used were of analytical grade and purchased from commercial sources as 
indicated in the respective following paragraphs. 
 
2.2   Cell lines and culture conditions 
HepG2 and Hep3B cells were purchased from the American Tissue Culture Collection 
(ATCC, Manassas, USA). Sk-Hep1 and HuH7 hepatocellular carcinoma cells were a kind gift 
from PD Dr. Thomas Armbrust (Department of Gastroenterology and Endocrinology, 
University Hospital Goettingen, Germany). Sk-chA1 and Mz-chA1 biliary adenocarcinoma 
cell lines were received from Prof. A. Knuth (University Hospital Zurich, Switzerland) 
(Knuth et al. 1985). 
The cells were incubated conventionally at 37°C in 5% CO2 atmosphere. Hep3B cells were 
cultured in Dulbecco’s MEM (Biochrom, Berlin, Germany) supplemented with 10% FCS 
(PAA, Cölbe, Germany), glutamine (1%), and penicillin/streptomycin 1%. HepG2 and Sk-
Hep1 cells were cultured in RPMI (Biochrom, Berlin, Germany) supplemented with 10% 
FCS, 2% glutamine, and 1% sodium pyruvate. HuH7, Sk-chA1, and Mz-chA1 cells were 
cultured in Dulbecco’s MEM supplemented with 10% FCS, 2% glutamine, and 1% sodium 
pyruvate. 
 
2.3   Irradiation and treatment of irradiated cells with TNF- 
Cells were irradiated with 6 MV photons at a dose rate of 2.4 Gy/min using a Varian Clinac 
600 C accelerator (Varian, Palo Alto, USA) as described previously (Christiansen et al. 2006; 
Christiansen et al. 2007; Moriconi et al. 2008; Christiansen et al. 2004; Tello et al. 2008; 




irradiation alone, cells were  additionally incubated with TNF- (PeproTech EC Ltd., 
London, UK). Thereby, doses of 100, 500, 5.000, and 50.000 units/ml were given 12 and 24 
hours prior to as well as 6 hours after irradiation. The initial dose of 100 U/ml was used based 
on our previous experiments, in which we demonstrated that this dose of TNF- causes the 
susceptibility of normal hepatocytes to TNF- mediated apoptosis (Christiansen et al. 2004). 
Sham irradiated cells served as controls in all experiments. 
 
2.4   Determination of cell survival (colony formation, apoptosis analysis, trypan blue 
exclusion) 
2.4.1   Colony formation 
To test for colony formation, 500 to 8000 cells were plated per T25 flask for low to high 
doses of radiation, respectively. Twelve days after the completion of treatment, the 
experiments were stopped. Cells were fixed, and stained with Crystal violet. Colonies with 
more than 50 cells were scored as survivors. Experiments were done in quadruplicate and 
repeated at least twice for each cell line. Cell survival was calculated with or without 
correction for effects induced by TNF-, and normalized radiation survival was fitted using 
the linear quadratic model: (lnS/S0 = -(D + D2)). S represents the surviving clones, S0 
represents the number of cells plated, D represents the radiation dose, and  and  stand for 
the alpha and beta coefficients, representing the initial slope and curvature of the fitted 
survival curves. 
2.4.2   Apoptosis analysis 
Apoptosis was determined 12, 24, 48, and 72 hours after irradiation with or without TNF- or 
sham irradiation. Fixed cells were stained with 2 µg/ml Hoechst 33342 (blue fluorescence) to 
visualize nuclear morphology and 10 µg/ml acridine orange (red fluorescence) to visualize 




Hamburg, Germany) were mixed together and applied in the dark for 10 minutes. Stained 
cells were then analysed immediately under a fluorescence microscope (Zeiss, Goettingen, 
Germany). Apoptotic cells were identified by the typical morphological changes in their 
nuclei, such as chromatin condensation or fragmentation. Pale blue cells with round nuclei 
were classified as normal viable cells, and cells displaying bright blue condensed nuclei (early 
apoptosis) or nuclei containing apoptotic bodies (late apoptosis) were classified as apoptotic 
cells. One hundred cells were scored five times for every sample analysed, and the apoptosis 
index, i.e. the relative proportion of apoptotic cells within the sample, was calculated. 
2.4.3   Trypan blue exclusion 
To test cell viability after treatment (irradiation ± TNF-, see above), living cells were 
analysed by trypan blue exclusion as follows: 0.5 ml 0.4% trypan blue (Sigma, St. Louis, 
USA) and 0.3 ml PBS (Biochrom, Berlin, Germany) were added to 0.1 ml of the cell 
suspension. After incubation, stained and unstained cells were counted using a 
haemocytometer. 
 
2.5   RNA isolation and quantitative real-time RT-PCR 
Total RNA from irradiated cells and sham irradiated controls was isolated after 
homogenisation in guanidinium isothiocyanate (Sigma) using the CsCl ultracentrifugation 
method (Chirgwin et al. 1979) as described previously (Ramadori et al. 1985). In preparation 
of real time PCR, reverse transcription of RNA samples was performed using the Invitrogen 
Superscript kit (Groningen, Netherlands). The instructions of the manufacturer were followed. 
Real time PCR analysis of cDNA was performed at 95-60°C for 45 cycles in the sequence 
detection system of an ABI Prism 7600 (Applied Biosystems, Darmstadt, Germany) in 
accordance with the manufacturers’ instructions, using Syber green reaction master mix (ABI 
Prism) and the following primers: Human TNF receptor I, forward; 5’-




TNF receptor II, forward; 5’-CTCAGGAGCATGGGGATAAA-3’, reverse; 5’-
AGCCAGCCAGTCTGACATCT-3’, human TNF-, forward; 5’-
CCCAGCCAGTCAGATCATCTTC-3’, reverse; 5’-AGCTGCCCCTCAGCTTGA-3’. Gene 
specific primers for β-actin were designed as described previously (Haller et al. 2004). All of 
our primers were synthesized by MWG Biotech (Ebersberg, Germany). In every RNA 
sample, β-actin mRNA is measured as housekeeping gene. Values were then compared with 
those obtained using the control RNA obtained from sham irradiated cells from each 
experimental series. The results were normalized to the housekeeping gene and fold change 
expression was calculated using threshold cycle (Ct) values. During real time RT-PCR, the 
cycle number at which gene expression of any specific gene under study reaches a 
predetermined threshold of detection is known as the “Ct-value”. The Ct-value (threshold 
cycle) is defined as “the fractional cycle number at which the fluorescence passes the fixed 
threshold”. The higher the Ct-value for the specific gene at a given time is, the lower the 
abundance of the specific mRNA. To calculate the relative changes, data representing gene 
expression after sham irradiation was set as 1 at the respective time points after treatment. 
 
2.6   Western blot analysis 
Cells at different times after treatment were lysed in hot Laemmli buffer (95°C) and processed 
with sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) under 
reducing conditions according to Laemmli (1970). The protein content of cellular lysates was 
calculated by the Coomassie Protein Assay (Pierce, Rockfordt, IL); β-actin was used as 
loading control. Proteins were transferred onto Hybond - ECL nitrocellulose hybridization 
transfer membranes according to Towbin et al. (1979). We performed immunodetection 
studies   according to the ECL Western blotting protocol. The primary antibody to IB 




rabbit immunoglobulins were each used at a 1/1000 dilution. Densitometric evaluation of the 
blots was performed using Scion Image Version Beta 2 (NIH) software. 
 
2.7   Statistical analysis 
Results are expressed as mean ± SD, and the significance of the difference between the means 







3.1   Colony formation 
Sensitivity to TNF- treatment, radiation, or a combination of TNF- and radiation of the 
analysed hepatobiliary tumour cell lines was first determined using a clonogenic assay. Cells 
were irradiated with graded single doses and incubated with 100 U/ml TNF- 6 hours after 
irradiation. Figure 1 A-E depicts cellular responses prior to correcting for TNF-induced 
effects on colony formation. Figure 1 F-J illustrates responses of cells after correction for 
TNF--induced effects on colony formation (normalized survival). All cell lines tested 
responded to radiation in a dose dependent manner. Surviving fractions at the clinically 
relevant single dose of 2 Gy were in a range between 68% and 37%, thus the cell lines 
represent a broad range of radiation sensitivity. Moreover, two cell lines, the hepatocellular 
carcinoma HepG2, and the biliary carcinoma Sk-chA1, exhibited a reduction in colony 
forming ability after TNF- treatment alone (figures 1A and 1D, respectively). However, the 
TNF-related toxicity did not translate into reduced radiation survival in any of the cell lines 
tested. (Figure 1).  
 
3.2   Determination of radiation and / or TNF-induced apoptosis 
Apoptosis of the analysed hepatocellular (HepG2, Hep3B, Sk-Hep1, HuH7) and 
cholangiocellular (Sk-chA1, Mz-chA1) cell lines after treatment with either 8 Gy irradiation 
with or without additional incubation with TNF- (100U, TNF- was applied 6 hours after 
irradiation) or TNF- alone was compared to sham treated cells. TNF- as well as radiation 
alone or in combination caused a statistically significant increase in apoptotic cells in all cell 




of apoptosis varying between cell lines. However, the combination of radiation and TNF- 
caused no statistically significant increase in apoptosis in terms of sensitization. 
 
3.3   Influence of the radiation and TNF-doses and the time point of exposure to TNF- 
in relation to irradiation on cell viability 
As we had already demonstrated that the additional incubation with 100U TNF- 6 hours 
after irradiation did not lead to enhanced radiosensitivity of the analysed hepatocellular and 
cholangiocellular carcinoma cells, we tested whether changes in either the radiation or TNF-
doses or the time point of exposure to TNF- in relation to irradiation would have any 
influence on cell viability. Therefore, cell viability of Hep3B cells after irradiation and 
additional exposure to TNF- was determined using trypan blue exclusion (Figure 3). The 
radiation and TNF-doses as well as the time point of exposure to TNF- in relation to 
irradiation was varied as follows: 100U TNF- 12 or 24 hours prior to 8 Gy irradiation, 500U 
TNF- 12 or 24 hours prior to 8 Gy irradiation, 5.000U TNF- 12 hours prior to or 6 hours 
after 8 or 25 Gy irradiation, 50.000U TNF- 12 hours prior to or 6 hours after 8 or 25 Gy 
irradiation. Please note that cell survival after irradiation and/or TNF- treatment does not 
differ between the different treatment groups with variation of the radiation and TNF- doses 
or variation of the time point of exposure to TNF- in relation to irradiation. 
 
3.4   Real time PCR analysis (TNF-receptors 1 /2 and TNF-alpha) 
Real time PCR analysis up to 72 hours after irradiation with either 8 Gy with or without 
additional incubation with TNF- (100U, TNF- was given 6 hours after irradiation) or TNF- 
alone compared to sham irradiated cells revealed no statistically significant radiation and / 
or TNF-induced changes in the hepatocellular and cholangiocellular carcinoma cells 




example for one hepatocellular (Sk-Hep1) and one cholangiocellular (Mz-chA1) cell line, 
respectively. Similarly, no statistically significant changes were found in the other 
hepatocellular (HepG2, Hep3B, HuH7) and cholangiocellular (Sk-chA1) cell lines (data not 
shown). 
Additionally, we tested whether radiation induces changes in TNF- expression in 
hepatocellular and cholangiocellular cell lines. Therefore, real time PCR analyses of total 
RNA extracted 1, 3, 6, 12, 24, 48, and 72 hours after 8 Gy irradiation were performed. Figures 
4e/f depict a radiation induced up-regulation of TNF- exemplarily for one hepatocellular 
(Sk-Hep1) and one cholangiocellular (Mz-chA1) cell line, respectively. Similarly, a 
statistically significant up-regulation was detected in the other hepatocellular (HepG2, 
Hep3B, HuH7) and cholangiocellular (Sk-chA1) cell lines (data not shown). 
 
3.5 Western blot analysis 
To demonstrate gene expression at the protein level, the amount of IB protein was analysed 
by Western blot. In doing so, we demonstrated that IB was expressed in Hep3B cultures up 
to 48 hours after irradiation with either 8 Gy with or without additional incubation with TNF- 
 (100U, TNF- was given 6 hours after irradiation) or TNF- alone, as well as after sham 
irradiation. However, no significant changes were observed after irradiation and / or TNF- 
treatment compared to sham irradiation, which could be confirmed through densitometric 







TNF- is a multifunctional cytokine with well documented protective and destructive 
capacities. In the liver, TNF- is involved in acute phase reactions (Ramadori et al. 1988) and 
seems to play a decisive role in early processes after therapeutic irradiation, which may later 
lead to unfavourable side effects (Tello et al. 2008). On the other hand, TNF- has reported 
effectiveness in the treatment of tumours, especially in combination with other cytokines or 
chemotherapeutics (Sugarman et al. 1985; Rutka et al. 1988; Zouboulis et al. 1990; Sugarman 
et al. 1987; Kirstein et al. 1986; Lewis et al. 1987; Tomazic et al. 1988; Shibayama 1989; 
Chapekar et al. 1989; Manda et al. 1987; Mueller et al. 1996; Mutch et al. 1990; Helson et al. 
1975; Zuber et al. 1988; Ha and Lau 1988; Rosenblum et al. 1988; Schmiegel et al. 1988; 
Schiller et al. 1987; Nobuhara et al. 1987; Naomoto et al. 1987; Fransen et al. 1986). 
However, the combined action of TNF- and radiation on tumour cells still remains 
unexplored. Only few reports to date have described additive to synergistic effects on cancer 
cells or experimental tumours derived from ovary (Manetta et al. 1990), glioma (Gridley et al. 
2003; Gridley et al. 2000; Baher et al. 1999), lung (Gridley et al. 1996), colon (Kim et al. 
2001), and prostate (Chung et al. 1998). Data on the combined action of TNF- and 
irradiation on tumours of the liver have not been published so far. This led us to analyse the 
combined action of TNF- and irradiation on hepatocellular or biliary adenocarcinoma cell 
lines in vitro. We demonstrated that all tumour cell lines responded to treatment solely by 
irradiation or TNF-; however, combined radiation and TNF- treatment did not enhance the 
reaction in terms of radiosensitization.  
Taking morphological signs of apoptosis as an endpoint, all cell lines exhibited an increase in 
apoptosis due to TNF- treatment, and two of them, HepG2 and SkchA1, even displayed 
reduced survival when clonogenic survival was evaluated. The reaction of HepG2 cells to 
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TNF- was also tested by Chapekar et al. in 1989, who found HepG2 cells to be insensitive to 
the inhibitory effects of TNF-. The discrepancy with the present study may be explained by 
different endpoints. Chapekar et al. analysed proliferation over 48 hours, while survival was 
determined after two weeks in our case. 
Some reports described dose dependent TNF- activity (Rutka et al. 1988; Zouboulis et al. 
1990; Lewis et al. 1987; Manda et al. 1987; Mutch et al. 1990; Ha and Lau 1988), or a 
dependence of synergism with other anti-cancer agents on the sequence of for example TNF- 
and actinomycin-D (Shibayama 1989). In our study, neither varying the radiation or TNF- 
dose nor the time point of TNF- exposure in relation to irradiation caused any TNF-
related enhancement in radiosensitivity for any of the cell lines analysed. This is also in 
contrast to results obtained by our group (Christiansen et al. 2004) with isolated normal 
hepatocytes, with which we were able to demonstrate that irradiation leads to susceptibility of 
hepatocytes to TNF-mediated apoptosis. To achieve this susceptibility, TNF- had to be 
administered between 6 hours and 18 hours after irradiation (Rave-Fränk et al. 2006).  
Normal cell types from other organs exhibit pronounced sensitivity to higher doses of TNF- 
as well. Mauerhoff et al. (1994) reported on the dose dependent impaired growth of human 
endothelial cells, and Manda et al. (1987) discovered cytotoxicity to mouse L929 fibroblasts. 
However, human fibroblasts were revealed to be insensitive to TNF- treatment in different 
studies (Chapekar et al. 1989; Nobuhara et al. 1987; Fransen et al. 1986).  
The different reactions of normal hepatic tissue and hepatic tumour cells to the modulation of 
radiation effects by a cytokine may open new treatment options in hepatocellular or biliary 
cancer. 
Previous studies performed by our working group have already demonstrated radiation 
induced TNF- release after liver irradiation in vivo (Christiansen et al. 2007) and release of 
TNF- by liver macrophages (Kupffer cells) after irradiation in vitro (Christiansen et al. 
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2004; Tello et al. 2008). Additionally, we have shown that irradiation leads to susceptibility 
of hepatocytes to TNF- mediated apoptosis and that the effect of TNF- on irradiated 
hepatocytes (hepatocellular death) could be overridden by TNF- antibodies (Christiansen et 
al. 2004). Based on these results, we hypothesize that anti-TNF- therapy might allow 
protection against radiation induced TNF-mediated cellular damage. Support for this 
hypothesis comes from data published by Huang et al. (2006). In a mouse model, they 
demonstrated that radiation increased liver TNFR1 transcription and that pretreatment with 
antisense oligonucleotides for TNFR1 resulted in the inhibition of liver TNFR1. Assessing 
radiation induced liver damage by serum aspartate aminotransferase and alanine 
aminotransferase, hepatocyte micronucleus formation, and apoptosis assays, they discovered 
that such pre-treatment with antisense oligonucleotides for TNFR1 before radiation reduced 
liver damage at all endpoints evaluated. Consequently, their study suggests that ionizing 
radiation activates apoptotic signalling through TNFR1 in the liver, and thus provides a 
rationale for anti-TNFR1 treatment to prevent radiation induced liver injury. 
One concern with respect to any potential clinical use of anti-TNF- or anti-TNF receptor 
therapy may be that such an approach not only protects normal liver but also liver tumours 
from cytoablative therapy. TNF- acts via two distinct receptors, namely TNFR1 and TNFR2 
(Vandenabeele et al. 1995), where TNFR1 initiates the majority of the biological activities of 
TNF-. TNFR1 is expressed on nearly all cell types, and possesses the death domain (DD). 
For this reason, TNFR1 is an important member of the death receptor family that shares the 
capability of inducing apoptotic cell death (Ashkenazi and Dixit 1998). However, besides this 
apoptotic signalling, TNFR1 is also able to transduce cell survival signals. 
In this study, we analysed TNF receptor 1 and 2 expression using real time PCR. All 
hepatocellular and cholangiocellular carcinoma cell lines studied exhibited TNF receptor 1 
and 2 expression. However, analysis up to 72 hours after irradiation with either 8 Gy with or 
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without additional incubation with TNF-, or TNF- alone, revealed no significant radiation 
and / or TNF-induced receptor expression changes when compared with sham irradiated 
cells. Similar results were reported by Shibayama (1989), Rutka et al. (1988), and Lewis et al. 
(1987). Therefore, modulation of TNFR expression may not be essential to TNF- related 
effects or aberrant signalling may be present in hepatobiliary tumour cells.  
In this study, a certain degree of apoptosis induction by TNF- or irradiation with 8 Gy was 
observed in all cell lines tested. The time course and the extent of apoptosis induction varied 
between the cell lines. However, the combination of TNF- and radiation never caused an 
increase in apoptotic cell death in terms of sensitization. Correspondingly, clonogenic survival 
was reduced by sole TNF- treatment in the hepatocellular carcinoma HepG2, and the biliary 
carcinoma Sk-chA1. Furthermore, TNF-related toxicity did not translate into reduced 
radiation survival after combined treatment. Accordingly, no radioenhancing effect of TNF- 
was observed in the other cell lines analysed.  
In order to explain the findings, we checked whether any described genetic changes of the cell 
lines might be related directly to the observed effects. It has been stated that, when compared 
with other cancers such as colon and breast cancers, gene mutations in HCC are not as 
frequent and that for example, unlike other solid tumours, mutations of Ras genes in hepatic 
cancer are rare (Wong and Ng 2008). Nevertheless, several genetic changes in hepato- and 
cholangiocellular cell lines have been described in the literature (Hu et al. 2004; Park et al. 
2006). To our knowledge however, no genetic changes that might be directly related to the 
observed effects have been described in the analysed cell lines. We therefore concentrated on 
the NFB/IB pathway, as apoptosis induction in tumour cells by cytoablative treatments 
such as chemotherapy or radiation therapy is well known and documented, and its relation to 
the NFB/IB pathway has been discussed frequently (Wang et al. 1996; Jeremias et al. 1998; 
Wang et al. 1999). Analysing hepatocellular carcinomas, Tietze et al. (2000) reported that the 
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inhibition of NFB enhanced apoptosis induced by TNF-, whereas IB had an anti-
apoptotic effect on chemotherapy induced programmed cell death. 
In normal hepatocytes, radiation induced sensitization to TNF-α mediated apoptosis involves 
the up-regulation of IκB expression, followed by an inhibition of NFκB and thus probably an 
impairment of the NFκB related survival signalling (Rave-Fränk et al. 2006; Luedde and 
Trautwein 2006). Furthermore, administration of IκB antisense oligonucleotides to 
hepatocytes prior to their irradiation significantly inhibited their susceptibility to TNF-
mediated apoptosis. In fact, the increment of apoptotic cells due to TNF-administration 6 
hours after irradiation was reduced to control levels at the time points 24 hours and 48 hours 
after irradiation (Rave-Fränk et al. 2006).  
In our study, HepG2 tumour cells were analysed with respect to IB expression. Western 
blots revealed a pronounced degree of protein expression. However, neither irradiation, TNF-
 administration, nor a combination of the two changed the levels of IB protein in these 
tumour cells, when observed over a period of 48 hours. 
Such differences in apoptosis signalling between normal hepatocytes and hepatobiliary tumor 
cells might well contribute to their different reactions to the combined radiation and TNF- 
treatment and is in favour of the clinical use of anti-TNF- or anti-TNF receptor therapy. 
Our findings suggest different approaches when considering TNF- and irradiation in the 
treatment of hepatobiliary tumours. On the one hand, the activity of TNF- against at least 
some tumours and its proven synergy with other anti-cancer agents may be integrated into 
multi modality protocols. Such protocols should favourably include modern radiotherapy 
techniques, as we found neither indication that TNF- will impair the efficacy of radiation 
treatment, nor that radiotherapy will eliminate the anti-tumour potential of TNF-. On the 
other hand, the use of anti-TNF- or anti-TNF receptor treatments has promising perspectives 
in the anticipation of unfavourable hepatic side effects of radiation treatment. In normal 
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hepatic cells, TNF- induced susceptibility to radiation induced apoptosis, something which 
was not observed in hepatic tumour cells. However, our data demonstrate that TNF- is up-
regulated after irradiation in the hepatocellular and cholangiocellular cell lines analysed, 
behaviour similar to that of normal hepatocytes. Such radiation induced up-regulation has also 
been described for various other tumour cell lines (Rübe et al. 2003; Liu et al. 2005). 
However, TNF- does not only have this anti-tumour effect via direct cytotoxicity, but also 
through variable mechanisms including monocyte mediated cytotoxicity or endothelial cell 
damage (Pennica et al. 1985; Feinman et al. 1987; Sato et al. 1986). In consequence, further in 
vivo studies are needed to confirm that anti-TNF- treatment may be implemented for 
protection against hepatocellular injury after irradiation, for liver or other abdominal 
malignancies without compromising tumour control. 
The different reactions of normal hepatic tissue and hepatic tumour cells to the modulation of 
the effects of radiation by a cytokine may open avenues to new treatment options in 





TNF- may exhibit antitumoral activity and can influence the reaction of both tumour and 
normal tissue to radiation. The aim of our study was to test the effect of TNF- and/or 
irradiation on hepatocellular (HepG2, Hep3B, Sk-Hep1, HuH7) and cholangiocellular (Sk-
chA1, Mz-chA1) tumour cell lines. Colony formation, apoptosis analysis, and trypan blue 
exclusion were used to assess cell viability. Doses of radiation (2-25Gy) and TNF- (100U-
50.000U) as well as their respective sequencing were varied (24, 12 hours before, 6 hours 
after). The expression of TNF- and TNF receptors 1/2 was determined using real time PCR; 
IB protein-expression was detected by Western blot. Sole irradiation induced a reduction in 
colony formation in all cell lines, sole TNF- in HepG2 and Sk-chA1 cells, only. No 
difference in apoptosis induction after TNF- or irradiation was observed. Cellular death 
induced by the combination of TNF- and radiation was not superior to the use of any of the 
two agents alone. All cell lines revealed radiation induced up-regulation of TNF-  while the 
extent of TNF receptor specific transcription did not change. Furthermore, radiation induced 
changes in IκBα expression were not detectable. Our data suggest that both TNF- and 
radiation may be treatment options for hepatocellular and cholangiocellular carcinomas. As 
TNF-α and radiation do not interact in terms of radiosensitization, anti-TNF-α treatment may 
have the potential to protect against hepatocellular injury after abdominal irradiation. 
However, further in vivo studies are needed to confirm that anti-TNF-α treatment does not 













































6.2   Legends to illustrations 
Figure 1. 
Analysis of radiosensitivity of hepatobiliary tumour cell lines using a clonogenic assay. Cells 
were irradiated with graded single doses and incubated with 100 U/ml TNF- 6 hours after 
irradiation. A-E: responses of cells before correction for TNF- induced effects on colony 
formation. F-J: responses of cells after correction for TNF- induced effects on colony 
formation (normalized survival). Dose response curves F-J were fitted by the linear quadratic 
equation: (lnS/S0 = -(D + D2)); in which S represents the surviving clones, S0 represents 
the number of cells plated, D represents the radiation dose, and  and  stand for the alpha 
and beta coefficients, representing the initial slope and curvature of the fitted survival curves. 
Experiments were done in quadruplicate and repeated at least twice for each cell line; mean ± 
SD are presented; *p<0.05 
 
Figure 2. 
Apoptosis of different hepatocellular (HepG2 [A], Hep3B [B], Sk-Hep1 [C], HuH7 [D]) and 
cholangiocellular (Sk-chA1 [E], Mz-chA1 [F]) lines after treatment with either 8 Gy 
irradiation ± additional incubation with TNF- (100U, TNF- was applied 6 hours after 
irradiation) or TNF- alone compared to sham irradiated cells (= control). Apoptotic cells 
were identified by the typical morphological changes in their nuclei such as chromatin 
condensation or fragmentation. Please note that treatment of the cells with radiation and/or 
TNF- caused a statistical significant increase in the number of apoptotic cells in comparison 








Survival of Hep3B cells after irradiation and additional exposure to TNF-. Viable cells were 
determined by trypan blue exclusion. The radiation and TNF- doses as well as the time point 
of exposure to TNF- in relation to irradiation was varied as follows: [A] 100U TNF- 12 or 
24 hours prior 8 Gy irradiation, [B] 500U TNF- 12 or 24 hours prior 8 Gy irradiation, [C] 
5.000U TNF- 12 hours prior or 6 hours after 8 or 25 Gy irradiation, [D] 50.000U TNF- 12 
hours prior or 6 hours after 8 or 25 Gy irradiation. Please note that cell survival after 
irradiation and/or TNF- treatment does not differ between the different treatment groups 
with variation of the radiation and TNF- doses or variation of the time point of exposure to 




[A], [B]) ([C], [D]: Gene expression of TNF receptors 1 and 2 in the hepatocellular cell line 
Sk-Hep1 and the cholangiocellular cell line Mz-chA1 after treatment with either 8 Gy 
irradiation ± additional incubation with TNF- (100U, TNF- was given 6 hours after 
irradiation) or TNF- alone measured using quantitative real time PCR with β-actin as 
housekeeping gene. To calculate relative changes, expression after sham irradiation (=control) 
was set as 1 at the respective time points after treatment. The receptors were expressed in both 
cell lines at all time points analysed following the respective treatment (mean ct-value for 
receptor 1: 22.9 ± 1 [Sk-Hep1] and 26.7 ± 2.2 [Mz-chA1], mean ct-value for receptor 2: 25.9 
± 0.9 [Sk-Hep1] and 25.9 ± 2 [Mz-chA1]). However, please note that expression levels 
remained unchanged after irradiation as well as TNF- treatment or the combination of both. 
31 
 
Similar results could be obtained for the other hepatocellular (HepG2, Hep3B, HuH7) and 
cholangiocellular (Sk-chA1) cell lines analysed in this paper (data not shown). n=3 
[E], [F]: Gene expression of TNF- in the hepatocellular cell line Sk-Hep1 and the 
cholangiocellular cell line Mz-chA1 after treatment with 8 Gy measured using quantitative 
real time PCR with β-actin as housekeeping gene. To calculate relative changes, expression 
following sham irradiation (=control) was set as 1 at the respective time points after 
treatment. The data reveal the statistically significant up-regulation of TNF-. Similar results 
could be obtained for the other hepatocellular (HepG2, Hep3B, HuH7) and cholangiocellular 
(Sk-chA1) cell lines analysed in this paper (data not shown). n=2, *p<0.05 
 
Figure 5. 
Western blot analysis of Hep3B cell cultures after treatment with either 8 Gy irradiation ± 
additional incubation with TNF- (100U, TNF- was applied 6 hours after irradiation) or 
TNF- alone compared to sham irradiated cells (= control). Data relating to IκBα and -actin 
expression are also given. The blot presented [A] depicts results representative of two 
experiments of two independent isolations. The graph displays densitometric analysis of the 
Western blot data normalized on -actin expression [B]. For the densitometric analysis, the 
expression directly after sham irradiation was set as 100%. Please note that no statistically 
significant changes could be measured. Annotations are as follows: 1 = sham irradiation just 
after treatment, 2 = 8 Gy just after treatment, 3 = sham irradiation 12 hours after treatment, 4 
= TNF- 12 hours after treatment, 5 = 8 Gy 12 hours after treatment, 6 = 8 Gy + TNF- 12 
hours after treatment, 7 = sham irradiation 24 hours after treatment, 8 = TNF- 24 hours after 
treatment, 9 = 8 Gy 24 hours after treatment, 10 = 8 Gy + TNF- 24 hours after treatment, 11 
= sham irradiation 48 hours after treatment, 12 = TNF-24 hours after treatment, 13 = 8 Gy 
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Abstract
Background: Tumour necrosis factor a (TNF-a) may exhibit antitumoral
activity and can influence the reaction of both tumour and normal tissue to
radiation. Aims: To test the effect of TNF-a and/or irradiation on hepatocel-
lular (HepG2, Hep3B, Sk-Hep1, HuH7) and cholangiocellular (Sk-chA1,
Mz-chA1) tumour cell lines. Methods: Colony formation, apoptosis analysis
and trypan blue exclusion were used to assess cell viability. Doses of radiation
(2–25 Gy) and TNF-a (100–50 000 U) as well as their respective sequencing
were varied (24 and 12 h before and 6 h after). The expression of TNF-a and
TNF receptors 1/2 was determined using real-time polymerase chain reaction
and IkBa protein expression was detected by Western blot. Results: Sole
irradiation induced a reduction in colony formation in all cell lines and sole
TNF-a in HepG2 and Sk-chA1 cells only. No difference in apoptosis induction
after TNF-a or irradiation was observed. Cellular death induced by the
combination of TNF-a and radiation was not superior to the use of any of
the two agents alone. All cell lines revealed that radiation induced upregula-
tion of TNF-a whereas the extent of TNF receptor-specific transcription
did not change. Furthermore, radiation-induced changes in IkBa expression
were not detectable. Conclusions: Our data suggest that both TNF-a
and radiation may be treatment options for hepatocellular and cholangiocel-
lular carcinomas. Because TNF-a and radiation do not interact in terms of
radiosensitization, anti-TNF-a treatment may have the potential to protect
against hepatocellular injury after abdominal irradiation. However, further
in vivo studies are needed to confirm that anti-TNF-a treatment does
not compromise tumour control and actually attenuates radiation-induced
liver injury.
Tumour necrosis factor a (TNF-a) is a multifunctional
cytokine produced mainly by activated macrophages, T
lymphocytes and natural killer cells and, to a lesser
extent, by a variety of other cells, including fibroblasts
and tumour cells. TNF-a is involved in disparate pro-
cesses such as apoptosis, cell survival, inflammation and
immunity. Its bioactivity is mainly regulated by two
TNF-a-binding receptors (1, 2). TNF-a is widely known
to induce haemorrhagical necrosis in a certain set of
tumour types. Earlier studies on the effect of TNF-a on
tumour cells in vitro mostly revealed slight antiprolifera-
tive and cytotoxic effects when TNF-a was administered
alone and synergistic effects with other cytokines and
chemotherapeutics (3–23).
Radiotherapy represents one of the therapeutic op-
tions for patients with malignancies. The efficacy of this
therapy is limited, among other things, by the fact that it
cannot be delivered without hitting normal, healthy
tissue surrounding the tumour, with radiation-induced
acute and chronic side effects. Radiation is known to
induce DNA damage and chromosomal instability of
cells both from tumorous and normal tissue (24). How-
ever, beyond this, there are further mechanisms involved
in the actions occurring after the exposure of cells and
tissue to ionizing radiation, such as radiation-induced
apoptosis (25) and radiation-induced changes in gene
expression (26–28).Share senior authorship.
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Radiation therapy (RT) has not played a significant
role in the management of hepatocellular carcinoma or
liver metastases because the liver has only limited toler-
ance to radiation, combined with the high risk of
potentially fatal radiation-induced liver disease (RILD).
However, given the advances in modern radiotherapy
techniques, for example taking into account the respira-
tory motion of the liver, the implementation of image
guiding or stereotactic treatment, radiotherapy may now
be applied to patients with a greater degree of safety (29).
Tumours are embedded in a rich cell microenviron-
ment and radiotherapy not only targets cancer cells but
also induces temporary and persistent changes in the
local tissue microenvironment (30). Thus, the effect of
radiation on the tumour cells may be the result of a
combined effect on tumour cells and on the cells of the
microenvironment, contributing to both efficacy and
toxicity (31). One of the mechanisms here may be
cell–cell interactions via pro-inflammatory cytokines
because radiation is known to induce an upregulation of
these agents in several cells, organs and tissues (32, 33).
Therefore, cytokine-mediated cell–cell interactions seem
to play a decisive role in the development of acute and
chronic normal tissue injuries following radiotherapy
(32, 33). Similarly, we recently demonstrated that cell–
cell interactions via pro-inflammatory cytokines are
involved in the early pathomechanisms following liver
irradiation, leading to hepatocellular death and influen-
cing radiation-induced gene expression (27, 28, 34, 35).
Therefore, we hypothesize that cytokine-mediated cell–
cell interactions may be an important initial step towards
RILD, which is a dose-limiting complication in the
radiotherapy of abdominal and, especially, hepatic ma-
lignancies (36, 37). Our data revealed that the pro-
inflammatory cytokine TNF-a is of particular interest in
the processes taking place after liver irradiation as radia-
tion causes hepatocytes to become susceptible to TNF-a-
mediated apoptosis (35). Therefore, radiation-induced
apoptosis of liver macrophages, Kupffer cells, may lead to
a release of TNF-a in the microenvironment (35) fol-
lowed by apoptosis of the irradiated hepatocytes by
radiation-induced upregulation of IkB expression (38).
During the radiotherapy of hepatobiliary malignan-
cies, TNF-a may not only influence hepatocytes and liver
macrophages but also hepatocellular or biliary tumour
cells. However, the effect of TNF-a and radiation, espe-
cially in combination, on the sensitivity of hepatocellular
and biliary tumour cells has yet to be determined.
Therefore, the aim of the present study was to evaluate
the influence of TNF-a and radiation alone or in
combination on the viability of several hepatocellular
and biliary tumour cells in vitro. Furthermore, radiation-
induced changes of TNF-a, TNF receptors 1 and 2 as well
as IkB expression were evaluated to elucidate the intra-
cellular mechanisms and the possible differences in the
radiation-induced changes in hepatocytes in which the
pro-apoptotic effect of TNF-a after irradiation requires
radiation-induced upregulation of IkB expression (38).
Material and methods
Reagents
All chemicals used were of analytical grade and pur-
chased from commercial sources as indicated in the
respective following paragraphs.
Cell lines and culture conditions
HepG2 and Hep3B cells were purchased from the Amer-
ican Tissue Culture Collection (ATCC, Manassas, VA,
USA). Sk-Hep1 and HuH7 hepatocellular carcinoma
cells were a kind gift from PD Dr Thomas Armbrust
(Department of Gastroenterology and Endocrinology,
University Hospital Goettingen, Goettingen, Germany).
Sk-chA1 and Mz-chA1 biliary adenocarcinoma cell lines
were received from Prof. A. Knuth (University Hospital
Zurich, Zurich, Switzerland) (39).
The cells were incubated conventionally at 37 1C in a
5% CO2 atmosphere. Hep3B cells were cultured in
Dulbecco’s modified Eagle’s medium (MEM) (Biochrom,
Berlin, Germany) supplemented with 10% fetal calf
serum (FCS) (PAA, Cölbe, Germany), glutamine (1%)
and penicillin/streptomycin 1%. HepG2 and Sk-Hep1
cells were cultured in RPMI (Biochrom) supplemented
with 10% FCS, 2% glutamine and 1% sodium pyruvate.
HuH7, Sk-chA1 and Mz-chA1 cells were cultured in
Dulbecco’s MEM supplemented with 10% FCS, 2%
glutamine and 1% sodium pyruvate.
Irradiation and treatment of irradiated cells with tumour
necrosis factor-a
Cells were irradiated with 6 MV photons at a dose rate of
2.4 Gy/min using a Varian Clinac 600 C accelerator
(Varian, Palo Alto, CA, USA) as described previously
(26–28, 34, 35, 38). Radiation doses of 2, 4, 8 and 25 Gy
were applied. Besides irradiation alone, cells were addi-
tionally incubated with TNF-a (PeproTech EC Ltd,
London, UK). Thereby, doses of 100, 500, 5000 and
50 000 U/ml were given 12 and 24 h before as well as 6 h
after irradiation. The initial dose of 100 U/ml was used
based on our previous experiments in which we demon-
strated that this dose of TNF-a causes the susceptibility
of normal hepatocytes to TNF-a-mediated apoptosis
(34). Sham-irradiated cells served as controls in all
experiments.
Determination of cell survival (colony formation,
apoptosis analysis and trypan blue exclusion)
Colony formation
To test for colony formation, 500–8000 cells were plated
per T25 flask for low to high doses of radiation respec-
tively. Twelve days after the completion of treatment, the
experiments were stopped. Cells were fixed and stained
with Crystal violet. Colonies with more than 50 cells were
scored as survivors. Experiments were performed in
quadruplicate and repeated at least twice for each cell
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line. Cell survival was calculated with or without correc-
tion for effects induced by TNF-a and normalized
radiation survival was fitted using the linear quadratic
model: (lnS/S0 = (aD1bD2)). S represents the surviv-
ing clones, S0 represents the number of cells plated, D
represents the radiation dose and a and b stand for the a
and b coefficients, representing the initial slope and the
curvature of the fitted survival curves.
Apoptosis analysis
Apoptosis was determined 12, 24, 48 and 72 h after
irradiation with or without TNF-a or sham irradiation.
Fixed cells were stained with 2 mg/ml Hoechst 33342
(blue fluorescence) to visualize nuclear morphology and
10 mg/ml acridine orange (red fluorescence) to visualize
both the nucleus and the cytoplasm (40). Both fluoro-
chromes (Sigma, Hamburg, Germany) were mixed to-
gether and applied in the dark for 10 min. Stained cells
were then analysed immediately under a fluorescence
microscope (Zeiss, Goettingen, Germany). Apoptotic
cells were identified by the typical morphological changes
in their nuclei, such as chromatin condensation or
fragmentation. Pale blue cells with round nuclei were
classified as normal viable cells and cells displaying bright
blue condensed nuclei (early apoptosis) or nuclei con-
taining apoptotic bodies (late apoptosis) were classified
as apoptotic cells. One hundred cells were scored five
times for every sample analysed and the apoptosis index,
i.e. the relative proportion of apoptotic cells within the
sample, was calculated.
Trypan blue exclusion
To test cell viability after treatment (irradiationTNF-a,
see above), living cells were analysed by trypan blue
exclusion as follows: 0.5 ml 0.4% trypan blue (Sigma, St
Louis, MO, USA) and 0.3 ml phosphate-buffered saline
(Biochrom) were added to 0.1 ml of the cell suspension.
After incubation, stained and unstained cells were
counted using a haemocytometer.
RNA isolation and quantitative real-time reverse
transcriptase polymerase chain reaction
Total RNA from irradiated cells and sham-irradiated con-
trols was isolated after homogenization in guanidinium
isothiocyanate (Sigma) using the CsCl ultracentrifugation
method (41) as described previously (42). In preparation
of real-time polymerase chain reaction (PCR), reverse
transcription of RNA samples was performed using the
Invitrogen Superscript kit (Groningen, the Netherlands).
The instructions of the manufacturer were followed. Real-
time PCR analysis of cDNA was performed at 95–60 1C for
45 cycles in the sequence detection system of an Abi Prism
7600 (Applied Biosystems, Darmstadt, Germany) in accor-
dance with the manufacturer’s instructions using a Sybr
green reaction master mix (Abi Prism) and the following
primers: Human TNF receptor I, forward: 50-GAGAGGC
CATAGCTGTCTGG-30, reverse: 50-GTTCCTTTGTGGCA
CTTGGT-30; human TNF receptor II, forward: 50-CTCAG
GAGCATGGGGATAAA-30, reverse: 50-AGCCAGCCAGTC
TGACATCT-30; human TNF-a, forward: 50-CCCAGCCA
GTCAGATCATCTTC-30, reverse: 50-AGCTGCCCCTCAG
CTTGA-30. Gene-specific primers for b-actin were de-
signed as described previously (43). All of our primers
were synthesized by MWG Biotech (Ebersberg, Germany).
In every RNA sample, b-actin mRNA is measured as the
housekeeping gene. Values were then compared with those
obtained using the control RNA obtained from sham-
irradiated cells from each experimental series. The results
were normalized to the housekeeping gene and fold change
expression was calculated using threshold cycle (Ct) values.
During real-time reverse transcriptase PCR, the cycle
number at which gene expression of any specific gene
under study reaches a predetermined threshold of detec-
tion is known as the ‘Ct-value’. The Ct-value is defined as
‘the fractional cycle number at which the fluorescence
passes the fixed threshold’. The higher the Ct-value for the
specific gene at a given time, the lower the abundance of
the specific mRNA. To calculate the relative changes, data
representing gene expression after sham irradiation were
set as 1 at the respective time points after treatment.
Western blot analysis
Cells at different times after treatment were lysed in hot
Laemmli buffer (95 1C) and processed with sodium
dodecyl sulphate polyacrylamide gel electrophoresis un-
der reducing conditions according to Laemmli (44). The
protein content of the cellular lysates was calculated by
the Coomassie Protein Assay (Pierce, Rockfort, IL, USA)
where b-actin was used as the loading control. Proteins
were transferred onto Hybond–ECL nitrocellulose hybri-
dization transfer membranes according to Towbin et al.
(45). We performed immunodetection studies according
to the ECL Western blotting protocol. The primary
antibody to IkB (Calbiochem, Frankfurt, Germany) was
used at 2.5 mg/ml solutions. Anti-mouse and anti-rabbit
immunoglobulins were each used at a 1/1000 dilution.
Densitometric evaluation of the blots was performed
using the SCION IMAGE Version Beta 2 (NIH) software
(Scion Corporation, Frederick, MD, USA).
Statistical analysis
Results are expressed as mean SD and the significance
of the difference between the means was assessed using




Sensitivity to TNF-a treatment, radiation or a combina-
tion of TNF-a and radiation of the analysed
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hepatobiliary tumour cell lines was first determined
using a clonogenic assay. Cells were irradiated with
graded single doses and incubated with 100 U/ml TNF-a
6 h after irradiation. Figure 1A–E depicts cellular re-
sponses before correcting for TNF-a-induced effects on
colony formation. Figure 1F–J illustrates responses of
cells after correction for TNF-a-induced effects on col-
ony formation (normalized survival). All cell lines tested
responded to radiation in a dose-dependent manner.
Surviving fractions at the clinically relevant single dose
of 2 Gy were in the range between 68 and 37%. Thus, the
cell lines represent a broad range of radiation sensitivity.
Fig. 1. Analysis of radiosensitivity of hepatobiliary tumour cell lines using a clonogenic assay. Cells were irradiated with graded single doses
and incubated with 100 U/ml tumour necrosis factor a (TNF-a) 6 h after irradiation. (A–E) Responses of cells before correction for TNF-a-
induced effects on colony formation. (F–J) Responses of cells after correction for TNF-a-induced effects on colony formation (normalized
survival). Dose response curves F–J were fitted by the linear quadratic equation: (lnS/S0 =  (aD1bD2)), in which S represents the surviving
clones, S0 represents the number of cells plated, D represents the radiation dose and a and b stand for the a and b coefficients, representing
the initial slope and curvature of the fitted survival curves. Experiments were performed in quadruplicate and repeated at least twice for each
cell line. The mean SD is presented. Po 0.05.
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Moreover, two cell lines, the hepatocellular carcinoma
HepG2 and the biliary carcinoma Sk-chA1, exhibited a
reduction in colony-forming ability after TNF-a treat-
ment alone (Fig. 1A and D respectively). However, the
TNF-a-related toxicity did not translate into reduced
radiation survival in any of the cell lines tested (Fig. 1).
Determination of radiation and/or tumour necrosis
factor-a-induced apoptosis
Apoptosis of the analysed hepatocellular (HepG2,
Hep3B, Sk-Hep1, HuH7) and cholangiocellular (Sk-
chA1, Mz-chA1) cell lines after treatment with either
8 Gy irradiation with or without additional incubation
with TNF-a (100 U, TNF-a was applied 6 h after irradia-
tion) or TNF-a alone was compared with sham-treated
cells. TNF-a as well as radiation alone or in combination
caused a statistically significant increase in apoptotic cells
in all cell lines tested when compared with sham treat-
ment (Fig. 2), with time dependence and extent of
apoptosis varying between the cell lines. However, the
combination of radiation and TNF-a caused no statisti-
cally significant increase in apoptosis in terms of sensiti-
zation.
Influence of the radiation and tumour necrosis factor-a
doses and the time point of exposure to tumour necrosis
factor-a in relation to irradiation on cell viability
As we had already demonstrated that the additional
incubation with 100 U TNF-a 6 h after irradiation did
not lead to enhanced radiosensitivity of the analysed
hepatocellular and cholangiocellular carcinoma cells, we
tested whether changes in either the radiation or the
TNF-a doses or the time point of exposure to TNF-a in
relation to irradiation would have any influence on cell
viability. Therefore, cell viability of Hep3B cells after
irradiation and additional exposure to TNF-a was deter-
mined using trypan blue exclusion (Fig. 3). The radiation
and TNF-a doses as well as the time point of exposure to
TNF-a in relation to irradiation was varied as follows:
100 U TNF-a 12 or 24 h before 8 Gy irradiation, 500 U
TNF-a 12 or 24 h before 8 Gy irradiation, 5000 U TNF-a
12 h before or 6 h after 8 or 25 Gy irradiation, 50 000 U
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Fig. 2. Apoptosis of different hepatocellular [HepG2 (A), Hep3B (B),
Sk-Hep1 (C), HuH7 (D)] and cholangiocellular [Sk-chA1 (E), Mz-chA1
(F)] lines after treatment with either 8 Gy irradiation additional
incubation with tumour necrosis factor a (TNF-a) (100 U, TNF-a was
applied 6 h after irradiation) or TNF-a alone compared with sham-
irradiated cells (control). Apoptotic cells were identified by the
typical morphological changes in their nuclei, such as chromatin
condensation or fragmentation. Please note that treatment of the
cells with radiation and/or TNF-a caused a statistically significant
increase in the number of apoptotic cells in comparison with controls
in all cell lines analysed. Mean SD are presented. Po0.05, n = 5.
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Fig. 3. Survival of Hep3B cells after irradiation and additional exposure to tumour necrosis factor a (TNF-a). Viable cells were determined by
trypan blue exclusion. The radiation and TNF-a doses as well as the time point of exposure to TNF-a in relation to irradiation was varied as
follows: (A) 100 U TNF-a 12 or 24 h before 8 Gy irradiation, (B) 500 U TNF-a 12 or 24 h before 8 Gy irradiation, (C) 5000 U TNF-a 12 h before or
6 h after 8 or 25 Gy irradiation and (D) 50 000 U TNF-a 12 h before or 6 h after 8 or 25 Gy irradiation. Please note that cell survival after
irradiation and/or TNF-a treatment does not differ between the different treatment groups with variation of the radiation and TNF-a doses or
variation of the time point of exposure to TNF-a in relation to irradiation. n = 3.
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Please note that cell survival after irradiation and/or
TNF-a treatment does not differ between the different
treatment groups with variation of the radiation and
TNF-a doses or variation of the time point of exposure
to TNF-a in relation to irradiation.
Real-time polymerase chain reaction analysis (tumour
necrosis factor receptors 1/2 and tumour necrosis factor a)
Real-time PCR analysis up to 72 h after irradiation with
either 8 Gy with or without additional incubation with
TNF-a (100 U, TNF-a was given 6 h after irradiation)
or TNF-a alone compared with sham-irradiated cells
revealed no statistically significant radiation and/or
TNF-a-induced changes in the hepatocellular and cho-
langiocellular carcinoma cells analysed. Figure 4A–D
illustrates the relative expressions of TNF receptors 1
and 2 as an example for one hepatocellular (Sk-Hep1)
and one cholangiocellular (Mz-chA1) cell line respec-
tively. Similarly, no statistically significant changes were
found in the other hepatocellular (HepG2, Hep3B,
HuH7) and cholangiocellular (Sk-chA1) cell lines (data
not shown).
Additionally, we tested whether radiation induces
changes in TNF-a expression in hepatocellular and
cholangiocellular cell lines. Therefore, real-time PCR
analyses of total RNA extracted 1, 3, 6, 12, 24, 48 and
72 h after 8 Gy irradiation were performed. Figure 4E and
F depicts a radiation-induced upregulation of TNF-a
exemplarily for one hepatocellular (Sk-Hep1) and one
cholangiocellular (Mz-chA1) cell line respectively. Simi-
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Fig. 4. (A–D) Gene expression of tumour necrosis factor (TNF)
receptors 1 and 2 in the hepatocellular cell line Sk-Hep1 and the
cholangiocellular cell line Mz-chA1 after treatment with either 8 Gy
irradiation additional incubation with TNF-a (100 U, TNF-a was
given 6 h after irradiation) or TNF-a alone measured using
quantitative real-time polymerase chain reaction (PCR) with b-actin
as the housekeeping gene. To calculate relative changes, expression
after sham irradiation (control) was set as 1 at the respective time
points after treatment. The receptors were expressed in both cell
lines at all time points analysed following the respective treatment
[mean Ct-value for receptor 1: 22.9 1 (Sk-Hep1) and 26.7 2.2
(Mz-chA1), mean Ct-value for receptor 2: 25.90.9 (Sk-Hep1) and
25.9 2 (Mz-chA1)]. However, please note that expression levels
remained unchanged after irradiation as well as TNF-a treatment or
the combination of both. Similar results could be obtained for the
other hepatocellular (HepG2, Hep3B, HuH7) and cholangiocellular
(Sk-chA1) cell lines analysed in this paper (data not shown). n = 3. (E,
F) Gene expression of TNF-a in the hepatocellular cell line Sk-Hep1
and the cholangiocellular cell line Mz-chA1 after treatment with
8 Gy measured using quantitative real-time PCR with b-actin as the
housekeeping gene. To calculate relative changes, expression
following sham irradiation (control) was set as 1 at the respective
time points after treatment. The data reveal the statistically
significant upregulation of TNF-a. Similar results could be obtained
for the other hepatocellular (HepG2, Hep3B, HuH7) and
cholangiocellular (Sk-chA1) cell lines analysed in this paper (data not
shown). n = 2. Po 0.05.
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in the other hepatocellular (HepG2, Hep3B, HuH7) and
cholangiocellular (Sk-chA1) cell lines (data not shown).
Western blot analysis
To demonstrate gene expression at the protein level, the
amount of IkBa protein was analysed by Western blot. In
doing so, we demonstrated that IkBa was expressed in
Hep3B cultures up to 48 h after irradiation with either
8 Gy with or without additional incubation with TNF-a
(100 U, TNF-a was given 6 h after irradiation) or TNF-a
alone as well as after sham irradiation. However, no
significant changes were observed after irradiation and/
or TNF-a treatment compared with sham irradiation,
which could be confirmed through densitometric analysis
(Fig. 5).
Discussion
Tumour necrosis factor-a is a multifunctional cytokine
with well-documented protective and destructive capa-
cities. In the liver, TNF-a is involved in acute phase
reactions (46) and seems to play a decisive role in the
early processes after therapeutic irradiation, which may
later lead to unfavourable side effects (35). On the other
hand, TNF-a has reported effectiveness in the treatment
of tumours, especially in combination with other cyto-
kines or chemotherapeutics (3–23). However, the com-
bined action of TNF-a and radiation on tumour cells still
remains unexplored. Only few reports to date have
described additive to synergistic effects on cancer cells
or experimental tumours derived from the ovary (47),
glioma (48–50), lung (51), colon (52) and prostate (53).
Data on the combined action of TNF-a and irradiation
on tumours of the liver have not been published so far.
This led us to analyse the combined action of TNF-a and
irradiation on hepatocellular or biliary adenocarcinoma
cell lines in vitro. We demonstrated that all tumour cell
lines responded to treatment solely by irradiation or
TNF-a. However, combined radiation and TNF-a treat-
ment did not enhance the reaction in terms of radio-
sensitization.
Taking morphological signs of apoptosis as an end-
point, all cell lines exhibited an increase in apoptosis due
to TNF-a treatment and two of them, HepG2 and
SkchA1, even displayed reduced survival when clono-
genic survival was evaluated. The reaction of HepG2 cells
to TNF-a was also tested by Chapekar et al. in 1989 (11),
who found HepG2 cells to be insensitive to the inhibitory
effects of TNF-a. The discrepancy with the present study
may be explained by different endpoints. Chapekar and
colleagues analysed proliferation over 48 h whereas sur-
vival was determined after 2 weeks in our case.
Some reports described dose-dependent TNF-a activ-
ity (4, 5, 8, 12, 14, 17) or a dependence of synergism with
other anticancer agents on the sequence of for example
TNF-a and actinomycin-D (10). In our study, neither
varying the radiation or TNF-a dose nor the time point
of TNF-a exposure in relation to irradiation caused any
TNF-a-related enhancement in radiosensitivity for any
of the cell lines analysed. This is also in contrast to results
obtained by our group (34) with isolated normal hepa-
tocytes, with which we were able to demonstrate that
irradiation leads to susceptibility of hepatocytes to TNF-
a-mediated apoptosis. To achieve this susceptibility,
TNF-a had to be administered between 6 and 18 h after
irradiation (38).
Normal cell types from other organs exhibit pro-
nounced sensitivity to higher doses of TNF-a as well.
Mauerhoff et al. (54) reported on the dose-dependent-
impaired growth of human endothelial cells and Manda
et al. (12) discovered cytotoxicity to mouse L929 fibro-
blasts. However, human fibroblasts were revealed to be
insensitive to TNF-a treatment in different studies (11,
21, 23).
The different reactions of normal hepatic tissue and
hepatic tumour cells to the modulation of radiation
effects by a cytokine may open new treatment options in
hepatocellular or biliary cancer.
Previous studies performed by our working group
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Fig. 5. Western blot analysis of Hep3B cell cultures after treatment
with either 8 Gy irradiation additional incubation with tumour
necrosis factor a (TNF-a) (100 U, TNF-a was applied 6 h after
irradiation) or TNF-a alone compared with sham-irradiated cells
(control). Data relating to IkBa and b-actin expression are also given.
The blot presented (A) depicts results representative of two
experiments of two independent isolations. The graph displays
densitometric analysis of the Western blot data normalized on b-
actin expression (B). For the densitometric analysis, the expression
directly after sham irradiation was set as 100%. Please note that no
statistically significant changes could be measured. Annotations are
as follows: 1 = sham irradiation just after treatment, 2 = 8 Gy just
after treatment, 3 = sham irradiation 12 h after treatment, 4 = TNF-a
12 h after treatment, 5 = 8 Gy 12 h after treatment, 6 = 8 Gy1TNF-a
12 h after treatment, 7 = sham irradiation 24 h after treatment,
8 = TNF-a 24 h after treatment, 9 = 8 Gy 24 h after treatment,
10 = 8 Gy1TNF-a 24 h after treatment, 11 = sham irradiation 48 h
after treatment, 12 = TNF-a 24 h after treatment, 13 = 8 Gy 24 h
after treatment and 14 = 8 Gy1TNF-a 24 h after treatment.
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release after liver irradiation in vivo (27) and release of
TNF-a by liver macrophages (Kupffer cells) after irradia-
tion in vitro (34, 35). Additionally, we have shown that
irradiation leads to susceptibility of hepatocytes to TNF-
a-mediated apoptosis and that the effect of TNF-a on
irradiated hepatocytes (hepatocellular death) could be
overridden by TNF-a antibodies (34). Based on these
results, we hypothesize that anti-TNF-a therapy might
allow protection against radiation-induced TNF-a-
mediated cellular damage. Support for this hypothesis
comes from data published by Huang et al. (55) in 2006.
In a mouse model, they demonstrated that radiation
increased liver TNFR1 transcription and that pretreatment
with antisense oligonucleotides for TNFR1 resulted in the
inhibition of liver TNFR1. Assessing radiation-induced
liver damage by serum aspartate aminotransferase and
alanine aminotransferase, hepatocyte micronucleus forma-
tion and apoptosis assays, they discovered that such
pretreatment with antisense oligonucleotides for TNFR1
before radiation reduced liver damage at all endpoints
evaluated. Consequently, their study suggests that ionizing
radiation activates apoptotic signalling through TNFR1 in
the liver and thus provides a rationale for anti-TNFR1
treatment to prevent radiation-induced liver injury.
One concern with respect to any potential clinical use
of anti-TNF-a or anti-TNF receptor therapy may be that
such an approach not only protects normal liver but also
liver tumours from cytoablative therapy. TNF-a acts via
two distinct receptors, namely TNFR1 and TNFR2 (56),
where TNFR1 initiates the majority of the biological
activities of TNF-a. TNFR1 is expressed on nearly all cell
types and possesses the death domain. For this reason,
TNFR1 is an important member of the death receptor
family that shares the capability of inducing apoptotic
cell death (57). However, besides this apoptotic signal-
ling, TNFR1 is also able to transduce cell survival signals.
In this study, we analysed TNF receptors 1 and 2
expression using real-time PCR. All hepatocellular and
cholangiocellular carcinoma cell lines studied exhibited
TNF receptors 1 and 2 expression. However, analysis up
to 72 h after irradiation with either 8 Gy, with or without
additional incubation with TNF-a, or TNF-a alone
revealed no significant radiation and/or TNF-a-induced
receptor expression changes when compared with sham-
irradiated cells. Similar results were reported by Shibaya-
ma et al. (10) in 1989, Rutka et al. (4) in 1988 and Lewis
et al. (8) in 1987. Therefore, modulation of TNFR
expression may not be essential to TNF-a-related effects
or aberrant signalling may be present in hepatobiliary
tumour cells.
In this study, a certain degree of apoptosis induction
by TNF-a or irradiation with 8 Gy was observed in all cell
lines tested. The time course and the extent of apoptosis
induction varied between the cell lines. However, the
combination of TNF-a and radiation never caused an
increase in apoptotic cell death in terms of sensitization.
Correspondingly, clonogenic survival was reduced by
sole TNF-a treatment in the hepatocellular carcinoma
HepG2 and the biliary carcinoma Sk-chA1. Furthermore,
TNF-a-related toxicity did not translate into reduced
radiation survival after combined treatment. Accord-
ingly, no radioenhancing effect of TNF-a was observed
in the other cell lines analysed.
In order to explain the findings, we checked whether
any described genetic changes of the cell lines might be
directly related to the observed effects. It has been stated
that, when compared with other cancers such as colon
and breast cancers, gene mutations in hepatocellular
carcinoma are not as frequent and that, for example,
unlike other solid tumours, mutations of Ras genes in
hepatic cancer are rare (58). Nevertheless, several genetic
changes in hepato- and cholangiocellular cell lines have
been described in the literature (59, 60). To our knowl-
edge, however, no genetic changes that might be directly
related to the observed effects have been described in the
analysed cell lines. We therefore concentrated on the
NFkB/IkB pathway because apoptosis induction in tu-
mour cells by cytoablative treatments such as chemother-
apy or RT is well known and documented and its relation
to the NFkB/IkB pathway has been frequently discussed
(61–63). Analysing hepatocellular carcinomas, Tietze
et al. (64) reported that the inhibition of NFkB enhanced
apoptosis induced by TNF-a whereas IkBa had an anti-
apoptotic effect on chemotherapy-induced programmed
cell death.
In normal hepatocytes, radiation-induced sensitiza-
tion to TNF-a-mediated apoptosis involves the upregu-
lation of IkB expression, followed by an inhibition of
NFkB and thus probably an impairment of the NFkB-
related survival signalling (38, 65). Furthermore, admin-
istration of IkB antisense oligonucleotides to hepatocytes
before their irradiation significantly inhibited their sus-
ceptibility to TNF-a-mediated apoptosis. In fact, the
increment of apoptotic cells due to TNF-a administra-
tion 6 h after irradiation was reduced to control levels at
the time points 24 and 48 h after irradiation (38).
In our study, Hep3B tumour cells were analysed with
respect to IkBa expression. Western blots revealed a
pronounced degree of protein expression. However,
neither irradiation, TNF-a administration nor a combi-
nation of the two changed the levels of IkBa protein in
these tumour cells, when observed over a period of 48 h.
Such differences in apoptosis signalling between nor-
mal hepatocytes and hepatobiliary tumour cells might
well contribute to their different reactions to the com-
bined radiation and TNF-a treatment and is in favour of
the clinical use of anti-TNF-a or anti-TNF receptor
therapy.
Our findings suggest different approaches when con-
sidering TNF-a and irradiation in the treatment of
hepatobiliary tumours. On the one hand, the activity of
TNF-a against at least some tumours and its proven
synergy with other anticancer agents may be integrated
into multimodality protocols. Such protocols should
favourably include modern radiotherapy techniques be-
cause we neither found an indication that TNF-a will
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impair the efficacy of radiation treatment nor that radio-
therapy will eliminate the antitumour potential of TNF-
a. On the other hand, the use of anti-TNF-a or anti-TNF
receptor treatments has promising perspectives in the
anticipation of unfavourable hepatic side effects of
radiation treatment. In normal hepatic cells, TNF-a-
induced susceptibility to radiation-induced apoptosis,
something that was not observed in hepatic tumour cells.
However, our data demonstrate that TNF-a is upregu-
lated after irradiation in the hepatocellular and cholan-
giocellular cell lines analysed, behaviour similar to that of
normal liver tissue. Such radiation-induced upregulation
has also been described for various other tumour cell
lines (66, 67). However, TNF-a does not only have this
antitumour effect via direct cytotoxicity but also through
variable mechanisms, including monocyte-mediated cy-
totoxicity or endothelial cell damage (68–70). In conse-
quence, further in vivo studies are needed to confirm that
anti-TNF-a treatment may be implemented for protec-
tion against hepatocellular injury after irradiation, for
liver or other abdominal malignancies without compro-
mising tumour control.
The different reactions of normal hepatic tissue and
hepatic tumour cells to the modulation of the effects of
radiation by a cytokine may open avenues to new
treatment options in hepatocellular or biliary cancer and
certainly deserves further investigation.
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